← Reviews
Open accessFull analysisJun 29, 2026

LEONORA Protocol: synbiotics after colorectal cancer surgery to reduce gastrointestinal symptom burden — RCT protocol

This paper reports only a trial protocol; no efficacy data have been generated — effect direction remains insufficient.

Evidence levelDNarrative / animal / in vitro / mechanistic
Study typerct
Sample206
Effect directionInsufficient
CertaintyVery low
Clinical applicabilityVery low
Overinterpretation risk1/5 · Low
PICO
PopulationAdults undergoing surgical resection for colorectal cancer, recruited at 10 German clinics (planned n = 206)
InterventionDaily oral synbiotic for 12 weeks: 50 billion CFU of 12 bacterial strains (weeks 1–12) plus stepwise inulin 3–10 g/day (weeks 5–12)
ComparatorDouble placebo: placebo capsules plus maltodextrin (organoleptic substitute for inulin)
OutcomeGastrointestinal quality of life (day 90); Post-operative infection rates; Cancer recurrence; Cancer survival; Blood-based inflammatory biomarkers; Fecal microbiome composition; Fecal and serum metabolome

Summary of findings

OutcomeEffect95% CICertaintyClinical relevanceNotes
Gastrointestinal quality of life (day 90)not reported (protocol only)Very low
Post-operative infection ratesnot reported (protocol only)Very low
Cancer recurrencenot reported (protocol only)Very low
Cancer survivalnot reported (protocol only)Very low
Blood-based inflammatory biomarkersnot reported (protocol only)Very low
Fecal microbiome compositionnot reported (protocol only)Very low
Fecal and serum metabolomenot reported (protocol only)Very low

Context

Colorectal cancer surgery, antibiotics, and chemotherapy profoundly disrupt the gut microbiome, causing chronic diarrhea and impaired quality of life in a substantial proportion of patients. Prior RCTs linked synbiotics to reduced post-operative infections and diarrhea, but gastrointestinal quality-of-life data remain sparse. LEONORA was designed to address this gap in a German surgical population.

What the study showed

The published article is exclusively a study protocol. No participants have been randomized, no clinical data have been collected, and no results are reported. No effect estimates, 95% CIs, or p-values arise from this document. Any efficacy claims derive from prior studies cited in the introduction, not from LEONORA data.

How it was done

Parallel-group, double-blind, placebo-controlled, multicenter RCT (10 centers, Germany). Planned sample: 206 participants (103 per arm). Intervention duration: 12 weeks. Primary endpoint assessed at 90 days post-surgery. Protocol registered and published in BMC Cancer (2026).

Effect magnitude

No effect size estimates are available. The sample size calculation was based on a hypothesized effect to be verified upon trial completion.

Risk of bias

This is a protocol publication: zero outcome data available. Bias risk not assessable (RoB 2 not applicable to protocols). Recruitment restricted to German centers limits generalizability. Adherence to a 12-week post-surgical intervention in oncology patients is a relevant operational challenge not addressed.

Interpretation limit

What this study does NOT prove

This study does NOT prove efficacy, safety, or any direction of effect of synbiotics on gastrointestinal quality of life after colorectal surgery. It is not generalizable beyond the German CRC surgical profile until results are published.

In clinical practice

No change in clinical practice is supported by this document. Clinicians should await trial results before considering synbiotics as standard post-colorectal-surgery care. The protocol may guide analogous study designs in other countries.

Limitations

This is a protocol publication: zero outcome data available. Bias risk not assessable (RoB 2 not applicable to protocols). Recruitment restricted to German centers limits generalizability. Adherence to a 12-week post-surgical intervention in oncology patients is a relevant operational challenge not addressed.

What is still missing

Primary and secondary results from LEONORA itself — expected after follow-up of all 206 patients is complete. Microbiome and metabolome data have not yet been generated.

Technical appendix

Version history

  • 1.0 · 2026-06-29 — Auto-generated under Evidence Standard v1.0

Microbiota Weekly

The week in microbiota evidence, in your language. Structured summaries, traceable to the source.